**Core tip:** The interactions between hepatitis C virus (HCV) and the host immune system in the liver play a key role in the immunopathogenesis of HCV-induced diseases. We showed here that (-)-epigallocatechin-3-gallate (EGCG) treatment could significantly increase the poly I:C-induced expression of TLR3, RIG-I and interferon (IFN)-λ1 in JFH-1-Huh7 cells. In addition, supplementation with EGCG enhanced poly I:C-mediated viral inhibition in JFH-1-Huh7 cells at both RNA and protein levels. Further investigation of the mechanisms showed that EGCG treatment significantly enhanced the poly I:C-induced expression of IFN-regulatory factor 9 and several IFN-stimulated genes. It would be interesting to investigate the possible use of EGCG in combination with current antiviral drugs for HCV therapy.

INTRODUCTION
============

Hepatitis C virus (HCV) is a hepatotropic virus, which holds a single-stranded, positive-sense RNA genome of 9.6 kb in length\[[@B1]\]. Currently, around 150 million people are chronically infected with HCV worldwide\[[@B2]\]. HCV infection causes liver diseases ranging from mild to moderate and severe, such as hepatitis, cirrhosis, and hepatocellular carcinoma\[[@B3]\]. The host immune responses play pivotal roles in the pathogenesis of viral infection, and the interplays of host antiviral immunity and HCV determine the outcomes of HCV infection\[[@B4]\]. It has been demonstrated that host immune responses are triggered by HCV, however, it is less effective in clearing the virus and leading a high rate of chronic infection in the majority of cases\[[@B5]\]. Acute HCV infection is accompanied by a spontaneous viral clearance in only about 20% to 30% of the subjects\[[@B2]\]. Recent studies showed that HCV has evolved several strategies to escape the attacks mediated by the host antiviral immunity\[[@B6]\]. Nonstructural (NS) 3/4A protease encoded by HCV genome has been showed to be able to impair the host antiviral innate immunity by disrupting the signaling of several pattern recognition receptors (PPRs), such as Toll-like receptor 3 (TLR3) and retinoic acid-inducible gene I (RIG-I)\[[@B7]-[@B9]\]. HCV NS4B blocks interferon (IFN) production by disrupting the interaction of STING with mitochondrial antiviral signaling protein (MAVS) and TBK1\[[@B10],[@B11]\]. Furthermore, host genetic factors play important roles in controlling HCV infection. Studies have shown that polymorphisms located in the *IFN-*λ region are related with the rate of viral clearance in HCV-infected individuals without treatment, as well as the sustained viral response (SVR) rate to the IFN-α-based treatment\[[@B12]-[@B15]\]. To date, tremendous progress has been made in understanding the biology of HCV and its related disease. Important advances in characterizing the HCV life cycle have led to the discovery of direct-acting antivirals (DAAs), which were developed for the effective treatment of chronic HCV infection\[[@B16],[@B17]\]. However, it is still challenging to dramatically decrease the incidence of HCV infection in the near future. High costs, low barrier to resistance-associated mutations, viral reinfection, failure of the DAAs in HCV-induced liver diseases, and lack of effective vaccines are obstacles to overcoming HCV infection globally\[[@B2]\].

(-)-Epigallocatechin-3-gallate (EGCG), the most abundant and bioactive catechin in green tea, possesses various physiological and pharmacological benefits to human health. Previous studies\[[@B18]-[@B20]\] revealed that EGCG exhibits abilities against viral infection and can prevent cardiovascular diseases, metabolic syndrome, neurodegenerative diseases, and cancer. It has been shown that EGCG can inhibit the replication of several viruses, such as human immunodeficiency virus\[[@B19]\], herpes simplex virus\[[@B21]\], as well as influenza virus\[[@B22]\]. Recent studies\[[@B23],[@B24]\] have revealed that EGCG can act as an inhibitor of HCV entry and limit intercellular spread of HCV. EGCG is a potent antioxidant that has both anti-inflammatory and anti-atherogenic properties\[[@B25]-[@B27]\]. Our previous study\[[@B27]\] indicated that EGCG inhibits lipopolysaccharide-induced inflammatory cytokine expression in microvascular endothelial cells. In addition, EGCG exhibits anticancer functions through inhibition of proteasome activity and induction of endoplasmic reticulum stress\[[@B28],[@B29]\]. Furthermore, it was also shown that EGCG increases the formation of lipid droplets and inhibits the secretion of very low-density lipoproteins in human hepatocytes\[[@B30]\].

Our recent study showed that HCV replication could impair the polyinosinic-polycytidylic acid (poly I:C)-triggered intracellular innate immune signaling pathway in hepatocytes\[[@B31]\]. Furthermore, we showed that EGCG possesses the ability to increase HCV dsRNA intermediate-induced expression of IFN-λ1 and IFN-stimulated genes (ISGs)\[[@B32]\]. In this study, we investigated the effect of EGCG on poly I:C-induced IFN pathway activation and its antiviral activities.

MATERIALS AND METHODS
=====================

EGCG
----

EGCG (purity, ≥ 95%) was purchased from SIGMA-ALDRICH, St. Louis, MO, United States (CAS\#: 989-51-5; Cat\# E4143). EGCG stock solution was prepared with sterile double distilled water at a concentration of 20 mmol/L.

Cells, virus, and reagents
--------------------------

The hepatoma cell line (Huh7), provided by Dr. Charles Rice (Rockefeller University, NY, United States), was maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 mg/mL). The generation of infectious HCV JFH-1 and infection of Huh7 cells (multiplicity of infection of 0.01) were carried out as previously described\[[@B33]\]. HCV JFH-1 infection of Huh7 cells was analyzed by immunostaining with mouse anti-HCV core antibody or by real-time reverse transcription-polymerase chain reaction (RT-PCR) for HCV RNA. LyoVec transfection reagent and poly I:C with a high molecular weight were purchased from InvivoGen (San Diego, CA, United States). An enzyme-linked immunosorbent assay (ELISA) kit for IFN-λ1 was purchased from eBioscience Inc. (San Diego, CA, United States). Mouse antibody against the HCV core antigen was purchased from ABR Affinity BioReagents, Thermo Scientific (Rockford, IL, United States). Hoechst 33342 was purchased from Molecular Probes (Carlsbad, CA, United States).

EGCG treatment and poly I:C stimulation
---------------------------------------

The JFH-1-infected Huh7 cells (72 h post-infection) were treated with EGCG (1-10 μmol/L) for 1 h prior to poly I:C (1 μg/mL) stimulation with LyoVec transfection reagent. The cells were collected for total RNA extraction after 24 h or 48 h of stimulation, and the supernatant (SN) was collected for ELISA after 48 h of stimulation. As a negative control of the transfection experiment, cells were incubated with the LyoVec transfection reagent without poly I:C.

RNA extraction and real-time RT-PCR
-----------------------------------

Total RNA from the cultured cells or SN was extracted with TRI Reagent (Molecular Research Center, Cincinnati, OH, United States) and subjected to reverse transcription (RT) using the RT system (Promega, Madison, WI, United States) with random primers for 1 h at 42 °C. The reaction was terminated by incubating the reaction mixture at 99 °C for 5 min, and the mixture was kept at 4 °C. The resulting cDNA was used as a template for quantitative real-time PCR. Real-time PCR was performed with 1/10 of the cDNA with the iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, United States). The amplified products were visualized and analyzed using the software MyiQ provided with the thermocycler (iCycler iQ real-time PCR detection system; Bio-Rad Laboratories). The oligonucleotide primers were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA, United States), and the sequences are shown in Table [1](#T1){ref-type="table"}. The cDNA was amplified by PCR, and the products were measured using SYBR green I (Bio-Rad Laboratories, Inc., Hercules, CA, United States). The data were normalized to the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and presented as the change in induction relative to that of the untreated control cells.

###### 

Primers used for real-time reverse transcription-polymerase chain reaction

  **Primer**   **Orientation**   **Sequences (5'-3')**
  ------------ ----------------- ----------------------------
  GAPDH        Forward           GGTGGTCTCCTCTGACTTCAACA
               Reverse           GTTGCTGTAGCCAAATTCGTTGT
  IFN-λ1       Forward           CTTCCAAGCCCACCCCAACT
               Reverse           GGCCTCCAGGACCTTCAGC
  TLR3         Forward           AGCCACCTGAAGTTGACTCAGG
               Reverse           CAGTCAAATTCGTGCAGAAGGC
  RIG-I        Forward           CTTGGCATGTTACACAGCTGAC
               Reverse           GCTTGGGATGTGGTCTACTCA
  IRF-9        Forward           GCATCAGGCAGGGCACGCTGCACCCG
               Reverse           GCCTGCATGTTTCCAGGGAATCCGG
  ISG15        Forward           GGCTGGGAGCTGACGGTGAAG
               Reverse           GCTCCGCCCGCCAGGCTCTGT
  ISG56        Forward           TTCGGAGAAAGGCATTAGA
               Reverse           TCCAGGGCTTCATTCATAT
  MxA          Forward           GCCGGCTGTGGATATGCTA
               Reverse           TTTATCGAAACATCTGTGAAAGCAA
  OAS-1        Forward           AGAAGGCAGCTCACGAAACC
               Reverse           CCACCACCCAAGTTTCCTGTA
  HCV          Forward           RAYCACTCCCCTGTGAGGAAC
               Reverse           TGRTGCACGGTCTACGAGACCTC

HCV: Hepatitis C virus; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; IFN: Interferon; TLR3: Toll-like receptor 3; RIG-I: Retinoic acid-inducible gene I.

ELISA
-----

IFN-λ1 protein expression was evaluated by ELISA. SN collected from EGCG and/or poly I:C-treated Huh7 cell cultures was directly tested for IFN-λ1 protein levels by ELISA, which was performed according to the manufacturer's instructions.

Statistical analysis
--------------------

Student's *t*-test was used to evaluate the significance of difference between the groups, and multiple comparisons were performed by regression analysis and one-way analysis of variance. All data are presented as the mean ± SD. Statistical analyses were performed with SPSS 11.5 for Windows. Statistical significance was defined as *P* \< 0.05.

RESULTS
=======

EGCG enhances poly I:C-induced IFN-λ1 expression in JFH-1-Huh7 cells
--------------------------------------------------------------------

In order to test the effect of EGCG on poly I:C-induced IFN-λ1 expression, we treated JFH-1-Huh7 cells (72 h post-infection) with EGCG (1-10 μmol/L) for 1 h before poly I:C treatment. The data showed that EGCG could significantly increase poly I:C-mediated *IFN-*λ*1* mRNA expression (Figure [1A](#F1){ref-type="fig"}), as well as IFN-λ1 protein production (Figure [1B](#F1){ref-type="fig"}), in a dose-dependent manner, whereas EGCG treatment alone had a negligible effect on IFN-λ1 expression in JFH-1-infected Huh7 cells\[[@B32]\].

![(-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 expression in JFH-1-Huh7 cells. JFH-1-infected Huh7 cells (72 h post-infection) were treated with EGCG at the indicated concentrations for 1 h prior to poly I:C (1 μg/mL) stimulation. Total RNA extracted from cells after 24 h of stimulation was subjected to real-time reverse transcription-polymerase chain reaction for the determination of IFN-λ1 and glyceraldehyde-3-phosphate dehydrogenase mRNA levels. The data are expressed as IFN-λ1 mRNA (A) levels relative (fold) to the control (vehicle only, which is defined as 1). After 48 h of stimulation, the supernatant (SN) was collected from the cell cultures for the determination of IFN-λ1 protein levels by enzyme-linked immunosorbent assay (B). The results shown are the mean ± SD of triplicate measurements representative of three experiments (Poly I:C *vs* LyoVec, ^a^*P* \< 0.05, ^b^*P* \< 0.01). IFN: Interferon; EGCG: (-)-Epigallocatechin-3-gallate.](WJG-23-5895-g001){#F1}

EGCG enhances poly I:C-induced TLR3 and RIG-I mRNA expression in JFH-1-Huh7 cells
---------------------------------------------------------------------------------

TLR3 and RIG-I are major cellular receptors that recognize pathogen-associated molecular patterns (PAMPs) during RNA virus infections. While EGCG (at a concentration lower than 10 μmol/L) treatment alone showed little effect on TLR3 and RIG-I expression\[[@B32]\], EGCG significantly increased the poly I:C-induced mRNA expression of *TLR3* (Figure [2A](#F2){ref-type="fig"}) and *RIG-I* (Figure [2B](#F2){ref-type="fig"}) in JFH-1-Huh7 cells.

![(-)-Epigallocatechin-3-gallate increases poly I:C-induced *TLR3* and *RIG-I* mRNA expression in JFH-1-infected Huh7 cells. JFH-1-infected Huh7 cells (72 h post-infection) were treated with (-)-epigallocatechin-3-gallate (EGCG) at the indicated concentrations for 1 h prior to poly I:C (1 μg/mL) stimulation. Total RNA extracted from the cells after 24 h of stimulation was evaluated for *TLR3* (A) and *RIG-I* (B) gene expression by real-time RT-PCR. The results shown are the mean ± SD of triplicate measurements representative of three experiments (Poly I:C *vs* LyoVec, ^a^*P* \< 0.05, ^b^*P* \< 0.01). TLR3: Toll-like receptor 3; RIG-I: Retinoic acid-inducible gene I.](WJG-23-5895-g002){#F2}

EGCG contributes to poly I:C-mediated inhibition of HCV replication
-------------------------------------------------------------------

Our previous study\[[@B32]\] showed that when we treated JFH-1-Huh7 cells with EGCG (1-10 μmol/L) alone, EGCG could not inhibit viral replication. We found that poly I:C treatment also had limited antiviral effect on the HCV-infected Huh7 cells (Figure [3](#F3){ref-type="fig"}). When the JFH-1-Huh7 cells were treated with EGCG 1 h before poly I:C stimulation, EGCG enhanced the poly I:C-mediated HCV inhibition in Huh7 cells in a dose-dependent manner (Figure [3](#F3){ref-type="fig"}). The inhibition of HCV by EGCG and poly I:C was confirmed by examining the intracellular (Figure [3A](#F3){ref-type="fig"}) and extracellular levels (Figure [3B](#F3){ref-type="fig"}) of HCV RNA and the level of HCV core protein (Figure [3C](#F3){ref-type="fig"}).

![(-)-Epigallocatechin-3-gallate contributes to poly I:C-mediated inhibition of hepatitis C virus replication. JFH-1-infected Huh7 cells (72 h post-infection) were treated with EGCG at the indicated concentrations for 1 h prior to poly I:C (1 μg/mL) stimulation. Intracellular (A) and extracellular (B) RNA was extracted from the JFH-1-infected Huh7 cells or culture SN after 48 h of stimulation and subjected to real-time reverse transcription-polymerase chain reaction for HCV and GAPDH RNA quantification. The intracellular hepatitis C virus (HCV) RNA level is expressed as the HCV RNA level relative (%) to the control (vehicle only, which is defined as 100%). Extracellular RNA levels are expressed as copies/mL. The results shown are the mean ± SD of triplicate cultures representative of three experiments (Poly I:C *vs* LyoVec, ^a^*P* \< 0.05, ^b^*P* \< 0.01). HCV core protein expression (C) was determined by immunofluorescence staining with an antibody against the HCV core protein (green) after 48 h of stimulation. The nuclei were stained with Hoechst 33342 (blue). One representative experiment is shown (original magnification: × 200). EGCG: (-)-Epigallocatechin-3-gallate.](WJG-23-5895-g003){#F3}

EGCG enhances poly I:C-induced IRF-9 expression in JFH-1-Huh7 cells
-------------------------------------------------------------------

As IRF-9 plays a critical role in the induction of antiviral ISGs, we further investigated the impact of EGCG on poly I:C-induced *IRF-9* mRNA expression. While EGCG alone had little impact on *IRF-9* mRNA expression (data not shown), EGCG pretreatment could significantly enhance poly I:C-induced *IRF-9* mRNA expression in JFH-1-Huh7 cells (Figure [4](#F4){ref-type="fig"}).

![(-)-Epigallocatechin-3-gallate increases poly I:C-induced IRF-9 expression in JFH-1-Huh7 cells. JFH-1-infected Huh7 cells (72 h post-infection) were treated with EGCG at the indicated concentrations for 1 h prior to poly I:C (1 μg/mL) stimulation. Total RNA extracted from the cells after 24 h of stimulation was subjected to real-time reverse transcription-polymerase chain reaction for the analysis of *IRF-9* gene expression. The results shown are the mean ± SD of triplicate measurements representative of three experiments (Poly I:C *vs* LyoVec, ^a^*P* \< 0.05, ^b^*P* \< 0.01). EGCG: (-)-Epigallocatechin-3-gallate.](WJG-23-5895-g004){#F4}

EGCG enhances poly I:C-induced expression of ISGs in JFH-1-Huh7 cells
---------------------------------------------------------------------

EGCG dose-dependently enhanced the poly I:C-induced expression of *ISG15* (Figure [5A](#F5){ref-type="fig"}), *ISG56* (Figure [5B](#F5){ref-type="fig"}), *MxA* (Figure [5C](#F5){ref-type="fig"}), and *OAS-1* (Figure [5D](#F5){ref-type="fig"}) in JFH-1-infected cells. However, EGCG treatment alone showed a negligible impact on the expression of those ISGs (data not shown).

![Effect of (-)-epigallocatechin-3-gallate on poly I:C-induced ISGs expression in JFH-1-infected Huh7 cells. JFH-1-infected Huh7 cells (72 h post-infection) were treated with EGCG at the indicated concentrations for 1 h prior to poly I:C (1 μg/mL) stimulation. Total RNA extracted from the cells after 24 h of stimulation was subjected to real-time reverse transcription-polymerase chain reaction for the determination of ISG and glyceraldehyde-3-phosphate dehydrogenase mRNA levels. The data are expressed as ISG15 (A), ISG56 (B), MxA (C), and OAS-1 (D) mRNA levels relative (fold) to the control (vehicle only, which is defined as 1). The results shown are the mean ± SD of triplicate measurements representative of three experiments (Poly I:C *vs* LyoVec, ^a^*P* \< 0.05, ^b^*P* \< 0.01). EGCG: (-)-Epigallocatechin-3-gallate.](WJG-23-5895-g005){#F5}

DISCUSSION
==========

In the current study, we showed that EGCG could enhance the poly I:C-induced innate immune responses in hepatocytes, which contributed to poly I:C-mediated HCV inhibition. Although poly I:C could induce the expression of *IFN-*λ*1* and several antiviral ISGs in JFH-1-infected Huh7 cells, the expression level was restricted by existing virus\[[@B31]\]. Our data indicated that EGCG significantly enhanced the poly I:C-induced expression of *IFN-*λ*1*, *TLR3*, *RIG-I*, *ISG15*, *ISG56*, *MxA*, and *OAS-1* in JFH-1-infected Huh7 cells. More importantly, pretreatment with EGCG enhanced poly I:C-mediated viral inhibition in JFH-1-infected cells. It has been demonstrated that IFN-λ could inhibit HCV replication, and recombinant IFN-λ1 was used as an antiviral drug in HCV treatment trials\[[@B34],[@B35]\]. The basic level of IFN-λ1 is very low in human hepatocytes, but it could be triggered by viral infections through activation of PPRs, such as TLR3\[[@B31],[@B36]\]. Our previous study\[[@B31]\] indicated that poly I:C treatment induces IFN-λ1 expression; however, HCV replication could impair the poly I:C-triggered TLR3 signaling pathway and decrease IFN-λ1 induction in Huh7 cells. In addition, HCV induced IFN-λ1 expression in primary human hepatocytes could resist against HCV\[[@B36]\]. Thus, the anti-HCV effect mediated by EGCG and poly I:C combination treatment in JFH-1-infected cells was likely through the enhancement of intracellular IFN-λ1 expression.

The interplays of HCV and the host antiviral immunity play important roles in the pathogenesis of HCV-related diseases. The innate immunity is the front line of host defenses against pathogen infections. TLRs and RIG-I-like receptors (RLRs) are major cellular receptors that recognize PAMPs during viral infections\[[@B37]\]. Among these TLR members, TLR3 is triggered by dsRNAs from the genome of some RNA viruses or intermediates formed during viral genome replication, such as HCV dsRNA intermediates\[[@B38],[@B39]\]. In addition to TLR3, RIG-I has been demonstrated to recognize HCV genome, inducing immune antiviral responses through the type I IFN signaling activation\[[@B40]\]. Our data showed that EGCG enhanced poly I:C-induced TLR3 and RIG-I expression in HCV-infected hepatocytes, which may contribute to the activation of IFN signaling to inhibit viral replication.

In order to maintain a persistent infection, HCV evolves several strategies to escape host antiviral immune responses\[[@B6]\]. It has been shown that a protease of HCV, NS3/4A, could disrupt both TLR3 and RIG-I activation through cleaving the cellular adaptor molecules, TRIF and MAVS, respectively\[[@B7]-[@B9]\]. HCV NS4B blocks IFN production by disrupting the interaction of STING with MAVS and TBK1\[[@B10],[@B11]\]. Studies also revealed that HCV impairs IRF-7 translocation, and inhibits both IFN-α and IFN-λ1 expression in hepatocytes\[[@B31],[@B41],[@B42]\]. Therefore, how to rescue the host antiviral immunity impaired by existing viruses is very important for the HCV eradication. In the current study, we found that EGCG enhanced poly I:C-induced IFN-λ1, TLR3, RIG-I and ISGs expression in JFH-1-Huh7 cells, showing that EGCG could improve intracellular antiviral immune responses in viral-infected cells.

In recent years, the development of effective DAAs has greatly increased the opportunity to cure HCV and achieve a milestone of HCV therapy. Following the approval of high effective DDAs in 2013, all-oral, IFN-free regimens were available for chronic HCV management\[[@B43]\]. Clinical applications of DAAs including inhibitors of NS3/4A, NS5A, and NS5B nucleotide or non-nucleotide inhibitors can achieve a high SVR rate of 90% to 100%\[[@B2],[@B44]\]. However, challenges still exist in the future management of HCV infection. DAAs are unavailable in poor areas and most of developing countries due to the high prices. It is also important to investigate the clinical effects of DAAs on advanced or decompensated liver diseases caused by HCV, as well as the clinical use of DAAs in HCV-infected children and pregnant women\[[@B45]\]. In addition, the majority of current DAAs have a low barrier to resistance, which leads to a high risk of selection of drug-resistant viral strains\[[@B46]\]. In the absence of an effective vaccine against HCV, reinfection is probable in cured patients under continuous HCV exposure\[[@B16]\].

In summary, EGCG enhances both poly I:C- and HCV dsRNA intermediate-induced innate immune responses in hepatocytes\[[@B32]\]. It would be interesting to investigate the possible use of EGCG in combination with current antiviral drugs for HCV therapy in the future.

COMMENTS
========

Background
----------

Chronic hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. New direct-acting antivirals (DAAs) therapies are able to achieve a sustainable virological response of up to 90% against the most prevalent HCV genotypes. However, continued efforts are still needed due to the high cost, low barrier to viral resistance, and the inability to treat HCV-related diseases of the DAAs as well as the lack of an effective HCV vaccine.

Research frontiers
------------------

The authors previously reported that HCV replication can impair the poly I:C-triggered innate immune response in hepatocytes. They also showed that epigallocatechin-3-gallate (EGCG) enhances HCV dsRNA intermediate-induced expression of IFN-λ1 and ISGs in hepatocytes. Effects of EGCG on the poly I:C-mediated expression of antiviral factors and inhibition of HCV were investigated in the present study. They found that EGCG increased poly I:C-induced IFN-λ1 and ISG expression and contributed to poly I:C-mediated HCV inhibition.

Innovations and breakthroughs
-----------------------------

The present study showed for the first time that EGCG can increase poly I:C-induced IFN-λ1 and ISG expression and contribute to poly I:C-mediated HCV inhibition.

Applications
------------

The authors demonstrated the effects of EGCG on poly I:C-triggered innate immune responses in hepatocytes. However, our observations only provided *in vitro* evidence due to the lack of *in vivo* data. It would be interesting to investigate the possible use of EGCG in combination with current antiviral drugs for HCV therapy in the future.

Terminology
-----------

EGCG is the most abundant and bioactive catechin in green tea and has been considered to have a number of physiological and pharmacological health benefits. Polyinosinic-polycytidylic acid (poly I:C) is a synthetic analog of dsRNA, a molecular pattern associated with viral infection. The average size of HMW poly I:C ranges from 1.5 kb to 8 kb.

Peer-review
-----------

This paper reports a well detailed investigation of the effect of EGCG on poly I:C-triggered intracellular innate immunity against HCV in hepatocytes. The authors demonstrated that EGCG had the ability to enhance poly I:C-induced innate immune responses in hepatocytes, which contributed to poly I:C-mediated HCV inhibition. Thus, it would be interesting to investigate the possible use of EGCG in combination with current antiviral drugs for HCV therapy in the future.
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